|
1
|
Chang SH, Luo S, Thomas TS, O'Brian KK,
Colditz GA, Carlsson NP and Carson KR: Obesity and the
transformation of monoclonal gammopathy of undetermined
significance to multiple myeloma: A population-based cohort study.
J Natl Cancer Inst. 109:djw2642016. View Article : Google Scholar
|
|
2
|
Popovic M, Lao N, Bedard G, Zeng L, Zhang
L, Cella D, Beaumont JL, Chiu N, Chiu L, Lam H, et al: Quality of
life in patients with advanced cancer using the functional
assessment of cancer therapy-general assessment tool: A literature
review. World J Oncol. 4:8–17. 2013.PubMed/NCBI
|
|
3
|
Tandon N, Rajkumar SV, LaPlant B,
Pettinger A, Lacy MQ, Dispenzieri A, Buadi FK, Gertz MA, Hayman SR,
Leung N, et al: Clinical utility of the revised international
staging system in unselected patients with newly diagnosed and
relapsed multiple myeloma. Blood Cancer J. 7:e5282017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Furukawa M, Ohkawara H, Ogawa K, Ikeda K,
Ueda K, Shichishima-Nakamura A, Ito E, Imai JI, Yanagisawa Y, Honma
R, et al: Autocrine and paracrine interactions between multiple
myeloma cells and bone marrow stromal cells by growth
arrest-specific gene 6 cross-talk with interleukin-6. J Biol Chem.
292:4280–4292. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mishra AK and Dingli D: Metformin inhibits
IL-6 signaling by decreasing IL-6R expression on multiple myeloma
cells. Leukemia. 33:2695–2709. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
De Oliveira MB, Fook-Alves VL, Eugenio
AIP, Fernando RC, Sanson LFG, de Carvalho MF, Braga WMT, Davies FE
and Colleoni GWB: Anti-myeloma effects of ruxolitinib combined with
bortezomib and lenalidomide: A rationale for JAK/STAT pathway
inhibition in myeloma patients. Cancer Lett. 403:206–215. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Altuvia Y, Landgraf P, Lithwick G, Elefant
N, Pfeffer S, Aravin A, Brownstein MJ, Tuschl T and Margalit H:
Clustering and conservation patterns of human microRNAs. Nucleic
Acids Res. 33:2697–2706. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang R, Wang ZX, Yang JS, Pan X, De W and
Chen LB: MicroRNA-451 functions as a tumor suppressor in human
non-small cell lung cancer by targeting ras-related protein 14
(RAB14). Oncogene. 30:2644–2658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang JY, Zhang K, Chen DQ, Chen J, Feng
B, Song H, Chen Y, Zhu Z, Lu L, De W, et al: MicroRNA-451:
Epithelial-mesenchymal transition inhibitor and prognostic
biomarker of hepatocellular carcinoma. Oncotarget. 6:18613–18630.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim Y, Powathil G, Kang H, Trucu D, Kim H,
Lawler S and Chaplain M: Strategies of eradicating glioma cells: A
multi-scale mathematical model with MiR-451-AMPK-mTOR control. PLoS
One. 10:e1143702015.
|
|
11
|
Yuan J, Lang J, Liu C, Zhou K, Chen L and
Liu Y: The expression and function of miRNA-451 in osteosarcoma.
Med Oncol. 32:3242015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gits CM, van Kuijk PF, Jonkers MB, Boersma
AWM, Smid M, van Ijcken WF, Coindre JM, Chibon F, Verhoef C,
Mathijssen RHJ, et al: MicroRNA expression profiles distinguish
liposarcoma subtypes and implicate miR-145 and miR-451 as tumor
suppressors. Int J Cancer. 135:348–361. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu X, Zhang A, Xiang J, Lv Y and Zhang X:
miR-451 acts as a suppressor of angiogenesis in hepatocellular
carcinoma by targeting the IL-6R-STAT3 pathway. Oncol Rep.
36:1385–1392. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chng WJ, Dispenzieri A, Chim CS, Fonseca
R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS,
Sonneveld P, et al: IMWG consensus on risk stratification in
multiple myeloma. Leukemia. 28:269–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kumar S, Paiva B, Anderson KC, Durie B,
Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, et
al: International myeloma working group consensus criteria for
response and minimal residual disease assessment in multiple
myeloma. Lancet Oncol. 17:e328–e346. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Flores-Montero J, Sanoja-Flores L, Paiva
B, Puig N, García-Sánchez O, Böttcher S, van der Velden VHJ,
Pérez-Morán JJ, Vidriales MB, García-Sanz R, et al: Next generation
flow for highly sensitive and standardized detection of minimal
residual disease in multiple myeloma. Leukemia. 31:2094–2103. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kolosenko I, Grander D and Tamm KP: IL-6
activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in
multiple myeloma. Curr Med Chem. 21:3042–3047. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu X, Wang J, Wang H, Yin G, Liu Y, Lei X
and Xiang M: REG3A accelerates pancreatic cancer cell growth under
IL-6-associated inflammatory condition: Involvement of a
REG3A-JAK2/STAT3 positive feedback loop. Cancer Lett. 362:45–60.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Suematsu S, Hibi M, Sugita T, Saito M,
Murakami M, Matsusaka T, Matsuda T, Hirano T, Taga T and Kishimoto
T: Interleukin 6 (IL-6) and its receptor (IL-6R) in
myeloma/plasmacytoma. Curr Top Microbiol Immunol. 166:13–22.
1990.PubMed/NCBI
|
|
21
|
Piddock RE, Marlein CR, Abdul-Aziz A,
Shafat MS, Auger MJ, Bowles KM and Rushworth SA: Myeloma-derived
macrophage inhibitory factor regulates bone marrow stromal
cell-derived IL-6 via c-MYC. J Hematol Oncol. 11:66–69. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Birmann BM, Neuhouser ML, Rosner B,
Albanes D, Buring JE, Giles GG, Lan Q, Lee IM, Purdue MP, Rothman
N, et al: Prediagnosis biomarkers of insulin-like growth factor-1,
insulin, and interleukin-6 dysregulation and multiple myeloma risk
in the multiple myeloma cohort consortium. Blood. 120:4929–4937.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao S, Li J, Zhang G, Wang Q, Wu C, Zhang
Q, Wang H, Sun P, Xiang R and Yang S: Exosomal miR-451a functions
as a tumor suppressor in hepatocellular carcinoma by targeting
LPIN1. Cell Physiol Biochem. 53:19–35. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meng YB, He X, Huang YF, Wu QN, Zhou YC
and Hao DJ: Long noncoding RNA CRNDE promotes multiple myeloma cell
growth by suppressing miR-451. Oncol Res. 25:1207–1214. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Balakrishnan I, Yang X, Brown J,
Ramakrishnan A, Torok-Storb B, Kabos P, Hesselberth JR and Pillai
MM: Genome-wide analysis of miRNA-mRNA interactions in marrow
stromal cells. Stem Cells. 32:662–673. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu SY, Deng SY, He YB and Ni GX: miR-451
inhibits cell growth, migration and angiogenesis in human
osteosarcoma via down-regulating IL-6R. Biochem Biophys Res Commun.
482:987–993. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gocke CB, McMillan R, Wang Q, Begum A,
Penchev VR, Ali SA, Borrello I, Huff CA and Matsui W: IQGAP1
scaffold-MAP kinase interactions enhance multiple myeloma
clonogenic growth and self-renewal. Mol Cancer Ther. 15:2733–2739.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mimura N, Hideshima T, Shimomura T, Suzuki
R, Ohguchi H, Rizq O, Kikuchi S, Yoshida Y, Cottini F, Jakubikova
J, et al: Selective and potent Akt inhibition triggers anti-myeloma
activities and enhances fatal endoplasmic reticulum stress induced
by proteasome inhibition. Cancer Res. 74:4458–4469. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Berenstein R, Nogai A, Waechter M, Blau O,
Kuehnel A, Schmidt-Hieber M, Kunitz A, Pezzutto A, Dörken B and
Blau IW: Multiple myeloma cells modify VEGF/IL-6 levels and
osteogenic potential of bone marrow stromal cells via
Notch/miR-223. Mol Carcinog. 55:1927–1939. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Matthews GM, de Matos Simoes R, Dhimolea
E, Sheffer M, Gandolfi S, Dashevsky O, Sorrell JD and Mitsiades CS:
NF-κB dysregulation in multiple myeloma. Semin Cancer Biol.
39:68–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
